{
    "eid": "2-s2.0-84960392114",
    "title": "Cost effectiveness analysis of different management strategies between best supportive care and second-line chemotherapy for platinum-resistant or refractory ovarian cancer",
    "cover-date": "2016-01-01",
    "subject-areas": [
        {
            "$": "Public Health",
            "@code": "2739"
        },
        {
            "$": "Oncology",
            "@code": "2730"
        },
        {
            "$": "Cancer Research",
            "@code": "1306"
        },
        {
            "$": "Epidemiology",
            "@code": "2713"
        }
    ],
    "keywords": [
        "Best supportive care",
        "Chemotherapy",
        "Cost-effectiveness analysis",
        "Recurrent-platinum ovarian cancer"
    ],
    "authors": [
        "Phanida Luealon"
    ],
    "citedby-count": 1,
    "ref-count": 20,
    "ref-list": [
        "The effect of prolonged cycles of chemotherapy on quality of life in gynaecologic cancer patients",
        "'Berek & Hacker's Gynecologic Oncology'",
        "Second-line chemotherapy with docetaxel and carboplatin in paclitaxel and platinum-pretreated ovarian, fallopian tube, and peritoneal cancer",
        "Third-line chemotherapy in platinum- and paclitaxel-resistant ovarian, fallopian tube, and primary peritoneal carcinoma patients",
        "Resource implications of palliative chemotherapy for ovarian cancer",
        "Treatment preferences in recurrent ovarian cancer",
        "Epithelial ovarian cancer",
        "Quality of life in ovarian cancer patients choosing to receive salvage chemotherapy or palliative treatment",
        "Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer",
        null,
        "The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy",
        "Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy",
        "'Thai National Health Technology Assessment Guidelines'",
        "Palliative therapy in advanced ovarian cancer: Balancing patient expectations, quality of life and cost",
        "Epithelial ovarian cancer/fallopian tube cancer/primary peritoneal cancer",
        "Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: A cost-effectiveness analysis",
        "Quality of life in gynecologic cancer survivors compared to healthy check-up women",
        "Cost effectiveness and strategic planning (WHO-CHOICE)",
        "Outcome of single agent generic gemcitabine in platinum-resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma"
    ],
    "affiliation": {
        "affiliation-city": "Bangkok",
        "affilname": "Chulalongkorn University",
        "affiliation-country": "Thailand"
    },
    "funding": []
}